Enstilar 0.005%-0.064% Topical Foam — Competitive Intelligence Brief

Enstilar 0.005%-0.064% Topical Foam (Enstilar 0.005%-0.064% Topical Foam) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid + Vitamin D analog combination. Area: Dermatology.

marketed Corticosteroid + Vitamin D analog combination Glucocorticoid receptor; Vitamin D receptor (VDR) Dermatology Small molecule

Target snapshot

Enstilar 0.005%-0.064% Topical Foam (Enstilar 0.005%-0.064% Topical Foam) — Psoriasis Treatment Center of Central New Jersey. Enstilar combines a potent corticosteroid (betamethasone dipropionate) and a vitamin D analog (calcipotriene) to reduce inflammation and normalize skin cell differentiation in psoriasis.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Enstilar 0.005%-0.064% Topical Foam TARGET	Enstilar 0.005%-0.064% Topical Foam	Psoriasis Treatment Center of Central New Jersey	marketed	Corticosteroid + Vitamin D analog combination	Glucocorticoid receptor; Vitamin D receptor (VDR)
Enstilar® foam	Enstilar® foam	Icahn School of Medicine at Mount Sinai	marketed	Topical corticosteroid + vitamin D analog combination	Glucocorticoid receptor; vitamin D receptor (VDR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid + Vitamin D analog combination class)

1. Psoriasis Treatment Center of Central New Jersey · 1 drug in this class